Biotech sector emerges from the summer doldrums to outperform the DJIA and NASDAQ

摘要

San Francisco-"With oil prices soaring in early August and consumer confidence weakening towards the end of themonth-not to mention a massive preoccupation with the upcoming US presidential election-the general markets continued to sag, but biotech managed to reverse its downward trend with the Burrill Biotech Selech Index posting a 2% gain for August," noted G. Steven Burrill, CEO of Burrill & Company. "The biotech market seems to have his its bottom and we can expect to see values continue to growin September, albeit slowly," he added. "There are those on Wall Street who believe that the market will improve in the fourth quarter-and historically, the forth quarter is a strong one-but we're unlikely to see as dramatic a comeback as some enthusiasts predict," he said.